CRISPR Without the Cut: How Scientists Switched Genes Back On by Rewriting Epigenetic “Anchors”

Once there was…
a powerful gene-editing tool called CRISPR that could fix biology by cutting DNA—but those cuts carried risks, including unintended changes and concerns like increased cancer risk in some therapeutic contexts.

Every day,
researchers worked to find safer ways to control genes—especially for diseases where the problem isn’t just a broken gene, but a gene that’s been switched off at the wrong time. One of the biggest culprits behind genes going silent is DNA methylation: tiny chemical “tags” called methyl groups that attach to DNA and often shut genes down.

Until one day,
scientists at the University of New South Wales (UNSW) and St Jude Children’s Research Hospital reported a breakthrough: a CRISPR-based method that can turn genes on without cutting the DNA at all—by editing the epigenome instead of the genome.

Because of that,
their approach uses epigenetic editing to precisely remove methyl groups from targeted DNA regions. In their study (published in Nature Communications), the team showed something researchers have debated for decades: methylation isn’t just a passive “marker.” It’s a direct controller of gene activity. When they removed methyl tags, genes turned on. When they added the methylation back, the genes went silent again.

Lead author Professor Merlin Crossley described these methyl groups as more like “anchors” than simple decorations—helping settle a long-running scientific argument about whether methylation truly causes gene silencing or merely correlates with it.

Because of that,
the biomedical implications are immediate and compelling—especially for sickle cell disease. Instead of trying to correct the faulty adult globin gene, the technique aims to reactivate the fetal globin gene. Fetal globin naturally produces a version of hemoglobin that carries oxygen effectively, and turning it back on could bypass the defective adult globin that causes sickling. Importantly, because this method avoids DNA cutting, it may offer a path to therapies with lower risk of unintended effects than traditional CRISPR approaches.

Co-author Professor Kate Quinlan highlighted this potential safety advantage: by not cutting DNA, the approach may reduce the chance of off-target damage and other complications.

Ever since then,
the idea of “gene editing” has started to shift. It no longer has to mean rewriting DNA letters with molecular scissors. It can mean reprogramming the biological switches that decide whether a gene is read or ignored. The team has already demonstrated precise control of gene expression in human cell lines, and the next steps include testing in animal models and expanding into broader applications—from other genetic conditions to possible uses in agriculture and future therapeutic development.

This breakthrough suggests a future where medicine doesn’t always need to change what’s written in our genetic code—sometimes it may be enough to remove the locks that keep helpful genes turned off.

Reference Source Links

• ScienceDaily (UNSW): http://www.sciencedaily.com/releases/2026/01/260104202813.htm